Grinshpoon Alexander, Margolis Anatoly, Weizman Abraham, Ponizovsky Alexander M
Mental Health Services, Ministry of Health, 2 Ben Tabai St., 93591 Jerusalem, Israel.
Alcohol Alcohol. 2007 Jul-Aug;42(4):340-6. doi: 10.1093/alcalc/agm041. Epub 2007 May 30.
Alcohol-dependent men commonly suffer from erectile dysfunction (ED) and men with ED are frequently chronic alcohol addicts. Sildenafil is used for treatment of ED caused by diverse factors. The aim of this study was to examine (i) the effect of sildenafil citrate (VIAGRA) on ED in alcohol dependent men, and (ii) whether the effective treatment of ED with sildenafil improves the patient's QoL and related emotional distress.
Fifty-four men with an ICD-10 diagnosis of alcohol dependence (AD) and concomitant ED agreed to enter an open-label trial, in which they were assigned to take 50 mg of sildenafil as add-on to a standard treatment for AD for 12 weeks. Fifty patients (92.3%) completed all baseline and endpoint assessments. Efficacy was evaluated using the International Index of Erectile Function (IIEF), Quality of Life Enjoyment and Satisfaction Questionnaire and General Health Questionnaire.
At endpoint, total IIEF scores had improved significantly (Delta=16.9), reflecting a 42% improvement (P<0.0001). A significant increase in the mean scores of each sexual function domain was also noted among all subjects. Sildenafil's positive effect was accompanied by a significant improvement (P<0.001) in satisfaction with overall QoL and specific life-domains, as well as a significant reduction in emotional distress scores (P<0.001).
The sildenafil add-on evaluated in this trial had a marked beneficial effect on ED and QoL, and was associated with a significant reduction in emotional distress among men with AD. The information obtained is valuable for both clinicians and policymakers in developing innovative therapeutic strategies for men with AD.
酒精依赖男性常患有勃起功能障碍(ED),而患有ED的男性也常常是慢性酒精成瘾者。西地那非用于治疗由多种因素引起的ED。本研究的目的是检验(i)枸橼酸西地那非(伟哥)对酒精依赖男性ED的影响,以及(ii)西地那非对ED的有效治疗是否能改善患者的生活质量(QoL)及相关情绪困扰。
54名国际疾病分类第十版(ICD - 10)诊断为酒精依赖(AD)且伴有ED的男性同意参加一项开放标签试验,在该试验中,他们被分配在AD标准治疗基础上加用50毫克西地那非,为期12周。50名患者(92.3%)完成了所有基线和终点评估。使用国际勃起功能指数(IIEF)、生活质量享受与满意度问卷以及一般健康问卷评估疗效。
在终点时,IIEF总分显著改善(差值 = 16.9),反映出改善了42%(P < 0.0001)。所有受试者的每个性功能领域的平均得分也显著增加。西地那非的积极作用伴随着总体QoL和特定生活领域满意度的显著改善(P < 0.001),以及情绪困扰得分的显著降低(P < 0.001)。
本试验中评估的西地那非附加治疗对ED和QoL有显著有益影响,并且与AD男性的情绪困扰显著降低相关。所获得的信息对于临床医生和政策制定者制定针对AD男性的创新治疗策略都很有价值。